Drug intelligence / Profile preview

ASHA-093

Development stage: Preclinical
Lead developer: First Atom Therapeutics
Modality: Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules

Overview

ASHA-093 is an early-stage therapeutic candidate developed by Asha Therapeutics for the treatment of cardiometabolic conditions. Discovered through the company's proprietary PRISM platform, ASHA-093 is designed as an "intramolecular glue," a type of small molecule that binds to a target protein to stabilize it in a specific, typically inactive, conformation. This approach allows for the modulation of proteins that are traditionally considered "undruggable" by standard inhibitors. While the specific molecular target of ASHA-093 remains undisclosed, the program represents an application of Asha's conformational-stabilization technology to metabolic and cardiovascular disease pathways. As of early 2024, the program is in the preclinical development phase.

Beyond the preview

Go deeper on ASHA-093.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ASHA-093.

Explore the full profile